Category Archives: Generics / ANDA

Amgen, Inc. et al. v. Sandoz Inc.

Docket Nos. 2015-1499 NEWMAN, LOURIE, CHEN December 14, 2017 Brief summary: DC’s dismissal of Amgen’s state law unfair competition and conversion claims was affirmed due to preemption by federal law (BCPIA). Summary: In its 2017 Sandoz v. Amgen decision relating … Continue reading

Posted in Biosimilars, Generics / ANDA | Leave a comment

Forest Laboratories, Inc. et al. v. Teva Pharmaceuticals USA, Inc.

Docket Nos. 2016-2550, -2553 LOURIE (C), REYNA, TARANTO December 11, 2017 Non-precedential Brief summary: DC finding of indefiniteness of claims requiring a comparison of immediate and extended release formulations affirmed. Summary: Forest appealed DC finding that all of the asserted … Continue reading

Posted in Generics / ANDA, Indefiniteness | Leave a comment

Amgen Inc. et al. v. Apotex Inc. et al.

Docket No. 2017-1010 LOURIE, O’MALLEY, TARANTO November 13, 2017 Non-precedential Brief summary: DC decision of no infringement of Amgen’s process patent by Apotex’s ABLA applications regarding Amgen’s Neulasta® and Neupogen® affirmed. Summary: Amgen appealed DC conclusion that Amgen failed to … Continue reading

Posted in Biosimilars, Generics / ANDA, Infringement | Leave a comment

Merck Sharp & Dohme Corp. v. Hospira, Inc.

Docket No. 2017-1115 NEWMAN, LOURIE, HUGES October 26, 2017 Brief Summary: DC conclusion that the asserted claims of its US 6,486,150 “directed to a stable process for preparing a stable formulation” of the antibiotic ertapenem (marketed by Merck as Invanz®) … Continue reading

Posted in Generics / ANDA, Obviousness | Leave a comment

Amgen, Inc. et al. v. Hospira, Inc.

Docket No. 2016-2179 DYK, BRYSON, CHEN August 10, 2017 Brief summary: Amgens’s appeal for lack of jurisdiction and petition for a writ of mandamus dismissed and denied, respectively, since DC denial of Amgen’s motion to compel discovery is “reviewable from … Continue reading

Posted in Biosimilars, Generics / ANDA | Leave a comment

Millenium Pharmaceuticals, Inc. v. Sandoz Inc. et al.

Docket No. 2015-2066 (several others) NEWMAN, MAYER, O’MALLEY July 17, 2017 Brief summary: DC decision that claims related to Millenium’s Velcade® are invalid for obviousness vacated and remanded. Summary: Millenium appealed DC decision that claims 20, 31, 49 and 53 … Continue reading

Posted in Generics / ANDA, Obviousness, Obviousness-Teaching Away | Leave a comment

Braintree Laboratories, Inc. v. Breckenridge Pharmaceutical, Inc.

Docket No. 2016-1731 NEWMAN, MOORE, WALLACH May 5, 2017 Non-precedential Brief Summary: DC claim construction (e.g., previous Novel decision “foreclosed the [DC’s] construction of ‘from about 100 ml to about 500 ml’”) and infringement decisions reversed (e.g., claimed effects of … Continue reading

Posted in Claim Construction, Generics / ANDA, Inducement to Infringe, Infringement | Leave a comment